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Abstract
Preeclampsia is a leading cause of perinatal morbidity and mortality. This disorder is thought to be multifactorial in origin,
with multiple genes, environmental and social factors, contributing to disease. One proposed mechanism is placental
hypoxia-driven imbalances in angiogenic and anti-angiogenic factors, causing endothelial cell dysfunction. Catechol-O-
methyltransferase (Comt)-deficient pregnant mice have a preeclampsia phenotype that is reversed by exogenous 2-
methoxyestradiol (2-ME), an estrogen metabolite generated by COMT. 2-ME inhibits Hypoxia Inducible Factor 1a,a
transcription factor mediating hypoxic responses. COMT has been shown to interact with methylenetetrahydrofolate
reductase (MTHFR), which modulates the availability of S-adenosylmethionine (SAM), a COMT cofactor. Variations in MTHFR
have been associated with preeclampsia. By accounting for allelic variation in both genes, the role of COMT has been
clarified. COMT allelic variation is linked to enzyme activity and four single nucleotide polymorphisms (SNPs) (rs6269, rs4633,
rs4680, and rs4818) form haplotypes that characterize COMT activity. We tested for association between COMT haplotypes
and the MTHFR 677 CRT polymorphism and preeclampsia risk in 1103 Chilean maternal-fetal dyads. The maternal ACCG
COMT haplotype was associated with reduced risk for preeclampsia (P=0.004), and that risk increased linearly from low to
high activity haplotypes (P=0.003). In fetal samples, we found that the fetal ATCA COMT haplotype and the fetal MTHFR
minor ‘‘T’’ allele interact to increase preeclampsia risk (p=0.022). We found a higher than expected number of patients with
preeclampsia with both the fetal risk alleles alone (P=0.052) and the fetal risk alleles in combination with a maternal
balancing allele (P,0.001). This non-random distribution was not observed in controls (P=0.341 and P=0.219, respectively).
Our findings demonstrate a role for both maternal and fetal COMT in preeclampsia and highlight the importance of
including allelic variation in MTHFR.
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Introduction
Preeclampsia (PE) affects 5–8% of pregnancies worldwide and is
characterized by hypertension and proteinuria after 20 weeks of
gestation[1]. Although preeclampsia remains a significant source
of maternal and perinatal mortality and morbidity, its etiology
remains unclear. A genetic susceptibility to preeclampsia has been
well established and genes involved with endothelial dysfunction,
oxidative stress, angiogenesis and thrombophilia have been
associated with preeclampsia[2–5].
It has long been recognized that preeclampsia is a placental
disorder that results in the maternal syndrome. Placental hypoxia
is a key feature of this condition and placentas from patients with
preeclampsia show shallow trophoblast invasion[6–8] and failure
of vascular transformation of the spiral arteries[9–11]. During
normal placentation, oxygen levels tightly control the balance
between angiogenic and anti-angiogenic factors to ensure
adequate remodeling of the maternal spiral arteries and sufficient
placental blood supply[12]. It is postulated that a hypoxia-driven
disruption of the angiogenic balance causes the placenta to
release factors that lead to intravascular inflammation[13–15],
endothelial dysfunction[16–20] and the maternal phenotype.
Indeed, abnormal concentrations of circulating angiogenic and
anti-angiogenic factors including soluble fms-like tyrosine kinase
(sFlt1), placental growth factor (PlGF), vascular endothelial growth
factor (VEGF), transforming growth factor beta (TGF-b), and
soluble endoglin (sENG) have been well documented in pre-
eclampsia[12,18,19,21–25]. Although abnormalities in these
factors have been consistently demonstrated, there is no discern-
able pattern that characterizes preeclampsia, suggesting that a
defect in an upstream regulator may contribute to the pathophys-
iology of preeclampsia.
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e166812-methoxyestradiol (2-ME) is a natural metabolite of estradiol
and it is generated by catechol-O-methyltransferase (COMT) in
the placenta. 2-ME is a compound with diverse biological activities
including inhibition of Hypoxia Inducible Factor 1a (HIF-
1a)[26,27]. HIF-1a is a transcription factor that mediates cellular
responses to hypoxia and its expression is altered in preeclamp-
sia[26–28]. Cytotrophoblastic invasion has also recently been
reported to be modulated by 2-ME during hypoxic conditions[29].
In collaboration with Kanasaki et al., we found that the Comt-
deficient pregnant mouse exhibits a preeclampsia phenotype
similar to that found in human preeclampsia, including hyperten-
sion, proteinuria and vascular and placental lesions; and the mouse
preeclampsia-like phenotype is reversed by administration of 2-
ME[27]. In this same report, circulating concentrations of 2-ME
and placental COMT activity were significantly reduced in
women diagnosed with preeclampsia, raising the possibility that
altered production of 2-ME may contribute to the pathophysiol-
ogy of preeclampsia by altering the placental response to
hypoxia[27]. Moreover, severe preeclampsia and fetal growth
restriction have been associated with reduced placental COMT
activity[30,31]. HIF-1a is an upstream regulator of many of the
factors implicated in the angiogenic balance and endothelial
dysfunction[12,28]. By modulating HIF-1a activity, COMT
represents a point at which this upstream regulator could be
disrupted.
Human allelic variation in COMT has been associated with
changes in enzyme activity levels[32,33]. COMT is one of several
enzymes that degrades catecholamines and is involved in vascular
and metabolic homeostasis, including dopamine, epinephrine,
norepinephrine, and catechol estrogens. The COMT enzyme is
involved in a wide variety of physiological processes, such as
prefrontal cortex function and lipid metabolism, and has been
implicated in diseases such as schizophrenia, pain sensitivity,
Parkinson’s disease, and cancer[33–37]. Previous studies investi-
gating the role of genetic variation in COMT have largely focused
on the single nucleotide polymorphism (SNP) rs4680 Val
158Met,
which has been associated with a modest 4-fold difference in
activity[32]. However, a recent functional analysis of four SNPs,
rs6269, rs4633, rs4818, and rs4680, demonstrated that enzymatic
activity is more precisely determined by three haplotypes of these
SNPs, which result in a 25-fold difference in enzyme activity[33].
Preeclampsia is thought to be multifactorial in origin with
multiple genes, environmental, and social factors acting in
conjunction to cause disease[38–40]. Variations in the methyle-
netetrahydrofolate reductase (MTHFR) gene have been associated
with elevated homocysteine, a risk factor for endothelial
dysfunction, vascular disease, and preeclampsia[41–44]. Some
previous studies have shown allelic variations in MTHFR to be
associated with preeclampsia, although others have failed to
replicate these associations[4,45,46]. MTHFR modulates the
availability of methyl groups[44], which are the cosubstrate for
COMT[32] and Roffman et al. recently showed that stratifying
COMT genotypes by MTHFR genotype revealed a role of COMT
in prefrontal cortex function[32,44,47].
In the present case-control study, we investigated the association
between COMT haplotypes and preeclampsia in 1,103 Chilean
maternal-fetal dyads. Haplotype frequencies were determined by
genotyping 4 SNPs from the COMT gene: rs6269, rs4633, rs4818,
and rs4680. Based on previous findings of haplotype-specific
differences in enzymatic activity and protein levels, we evaluated
the relationship of the functional variation linked to COMT
haplotype and preeclampsia[33]. Finally, we assessed whether the
relationship between COMT and preeclampsia was influenced by
MTHFR.
Results
Table 1 displays the demographic and clinical characteristics of
mothers and neonates from pregnancies with preeclampsia as well
as controls. No significant differences were observed in maternal
age or neonatal sex between groups. Consistent with previous
epidemiologic studies, patients with preeclampsia showed a
significantly higher body mass index (BMI, P,0.001) and fewer
previous live births (P=0.007). In accordance with preeclampsia
resulting in intrauterine growth restriction and indicated preterm
birth, offspring born to women with preeclampsia showed a
significantly lower gestational age at delivery and birthweight
(P,0.001).
Single SNP analysis revealed no associations between COMT
polymorphisms rs6269, rs4633, rs4818, and rs4680 and pre-
eclampsia in either maternal or fetal samples (Table S1). All SNPs
were found to be in Hardy-Weinberg equilibrium in the maternal
and fetal control samples separately. However, haplotype analysis
showed the four SNPs to be in very high linkage disequilibrium
(LD) for both maternal and fetal samples (Table S2). Three main
haplotypes were identified: ACCG, ATCA, and GCGG (SNP
order: rs6269, rs4633, rs4818, rs4680) and correspond to the low,
intermediate, and high enzyme activities of COMT, respectively,
identified by Nackley and colleagues[33].
The haplotype analysis of COMT frequency differences between
cases and control subjects is shown in Table 2. A global test of
differences among haplotypes reached statistical significance for
maternal samples, but not for fetal samples (P=0.016 and
P=0.116 respectively). Separate tests for haplotype-specific effects
on disease class resulted in significant results for both the maternal
(P=0.004) and fetal (P=0.038) ACCG haplotype (Table 2). This
haplotype was observed more frequently in controls than cases for
both maternal and fetal samples, indicating a possible protective
effect. To control for the correlation of genotypes inherent in
maternal-fetal dyads, we conditioned the maternal ACCG
haplotype by the respective fetal ACCG haplotype. This resulted
in only a significant effect of the maternal ACCG haplotype
(maternal P=0.041; fetal P=0.446) on risk for disease and
indicated that the effect of the ACCG haplotype was maternally
derived and initial significant result for the fetal ACCG haplotype
was likely a result of the correlation of the fetal-maternal genotype.
Additional multiple logistic regression analysis was performed to
include risk factors for preeclampsia (maternal age, BMI, and
previous live births). Results of a final regression model, which
only included covariates, found to be significant in this population
is shown in Table 3. Only the maternal ACCG haplotype
Table 1. Maternal and fetal characteristics of pregnancies
diagnosed with preeclampsia and controls.
Preeclampsia Controls P-value
Number of dyads 528 575 -
Maternal Age (years) 26.3 (7.5) 26.1 (6.2) 0.692
BMI (kg/m
2) 26.4 (5.4) 24.5 (4.4) ,0.001
Previous live births 0.80 (1.19) 0.99 (1.08) 0.007
Birthweight (grams) 2805.7 (815.7) 3423.2 (303.0) ,0.001
Gestational age at delivery
(weeks)
36.8 (3.4) 39.7 (1.1) ,0.001
Fetal sex (% female) 45.8 53.3 0.492
Data are presented as means (SD). BMI, body mass index.
doi:10.1371/journal.pone.0016681.t001
COMT Variation and Preeclampsia
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16681(maternal P=0.034, fetal P=0.419) was observed to have a
significant effect and was associated with a decreased risk of
preeclampsia (OR=0.796; 95% CI: 0.646, 0.982). Increased BMI
was associated with an increased risk for preeclampsia
(OR=1.108; 95% CI: 1.076, 1.142) and a larger number of previous
live births decreased the risk for preeclampsia (OR =0.782; 95%
CI: 0.695, 0.880).
Nackley et al. demonstrated in a mammalian expression system
that COMT haplotypes resulted in an ordered progression of
enzyme activity with the ACCG haplotype showing a 18–25 fold
decrease in activity and the ATCA haplotype showing a 2.5–3 fold
decrease in activity compared to the GCGG high activity
haplotype[33]. Results of a multiple logistic regression model that
included maternal and fetal terms to reflect enzymatic activity of
the COMT haplotypes (i.e., each coded as an ordinal variable),
maternal BMI, and previous live births are shown in Table 4.
When maternal and fetal terms were analyzed separately, both
show a significant positive relationship with increasing enzymatic
activity and preeclampsia risk (P=0.003 and P=0.014 respec-
tively). However, when both maternal and fetal terms were
included in the same model, again the fetal association decreased
in significance (P=0.561) and the maternal ordered COMT
haplotypes approached significance (P=0.061).
Obesity is a major risk factor for preeclampsia and our results
demonstrated BMI to be strongly associated with preeclampsia in
this population[48]. COMT metabolizes catecholamines, which
are known to modulate lipid mobilization[49]. Several studies
have found modest associations between obesity and the rs4680
(Val
158Met) SNP of COMT[50,51]. The potential for COMT to
contribute to preeclampsia risk through maternal BMI led us to
investigate whether the association between maternal COMT
haplotype and preeclampsia risk in our study could be explained
by a relationship between COMT and BMI. PLINK was used to
test for allelic associations between individual SNPs and BMI,
where BMI was the quantitative phenotype. Haplotype frequen-
cies were also generated in PLINK based on the four COMT SNPs
and haplotype-specific tests were performed to test for frequency
differences in association with BMI. Table 5 shows results for
analyses that tested the relationship between maternal COMT and
BMI in our study population. No significant associations between
COMT haplotypes or individual maternal SNPs and BMI were
observed.
Table 2. COMT haplotype analysis for mothers and fetuses with and without preeclampsia.
Group Haplotype Frequency Preeclampsia Frequency Controls Chi-square DF P-value
Maternal Global Test 8.260 2 0.016
ATCA 0.373 0.348 1.531 1 0.216
GCGG 0.310 0.277 2.807 1 0.094
ACCG 0.317 0.375 8.112 1 0.004
Fetal Global Test 4.308 2 0.116
ATCA 0.381 0.359 1.302 1 0.254
GCGG 0.302 0.283 0.907 1 0.341
ACCG 0.318 0.360 4.308 1 0.038
COMT haplotype SNP order: rs6269, rs4633, rs4818, rs4680. DF, degrees of freedom. Maternal and fetal samples were analyzed separately. The Global test of association
indicated that, in maternal samples, a significant difference in allele frequencies between cases and controls existed amongst the COMT haplotypes. When haplotypes
were tested individually, both the maternal and fetal ACCG COMT haplotypes were found more frequently in controls than cases.
doi:10.1371/journal.pone.0016681.t002
Table 3. Logistic regression model of primary risk factors for
preeclampsia including presence of the ACCG COMT
haplotype.
Term Estimate (S.E.) P-value Odds Ratio (95% C.I.)
Maternal ACCG 20.228 (0.107) 0.034 0.796 (0.646, 0.982)
Fetal ACCG 20.092 (0.114) 0.419 0.912 (0.729, 1.140)
Maternal BMI 0.103 (0.015) ,0.001 1.108 (1.076, 1.142)
Previous live births 20.246 (0.060) ,0.001 0.782 (0.695, 0.880)
Intercept 22.289 (0.378) ,0.001 -
COMT haplotype SNP order: rs6269, rs4633, rs4818, rs4680. S.E., standard error;
C.I., confidence interval; BMI, body mass index. When both maternal and fetal
ACCG haplotypes from the maternal-fetal dyads were included in a single
model, the maternal ACCG COMT remained significantly associated with
reduced risk for preeclampsia. The fetal ACCG COMT haplotype is not associated
with risk for preeclampsia after correcting for shared genetics between the
mother and fetus.
doi:10.1371/journal.pone.0016681.t003
Table 4. Logistic regression model of primary risk factors for
preeclampsia including COMT haplotype specified according
to reported enzymatic activity.
Term
Estimate
(S.E.) P-value
Odds Ratio
(95% C.I.)
Maternal haplotypes * 0.166 (0.089) 0.061 1.180 (0.992, 1.406)
Fetal haplotypes
{ 0.052 (0.090) 0.561 1.053 (0.883, 1.257)
Maternal BMI 0.081 (0.019) ,0.001 1.084 (1.045, 1.126)
Previous live births 20.236 (0.076) 0.002 0.790 (0.680, 0.917)
Intercept 22.560 (0.529) ,0.001
COMT haplotype SNP order: rs6269, rs4633, rs4818, rs4680. S.E., standard error;
C.I., confidence interval; BMI, body mass index. Ordered COMT haplotypes:
1=ACCG/ACCG, 2=ACCG/ATCA, 3= ATCA/ATCA, 4=ATCA/GCGG, 5=GCGG/
GCGG. Haplotypes were ordered from 1 (low activity) to 5 (high activity) in
accordance with reported information on enzyme activity[33]. Maternal
haplotypes showed increased risk for preeclampsia as haplotypes moved from
low to high activity alleles.
*If maternal term fitted in model without fetal haplotypes P=0.003, OR =1.221
(1.073, 1.390).
{If fetal term fitted in model without maternal haplotypes P=0.014, OR =1.179
(1.034, 1.345).
doi:10.1371/journal.pone.0016681.t004
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both through a single gene effect and an interaction with COMT
was studied[4,45,47]. The rs4680 loci of COMT encodes for an
amino substitution (Val
158Met) and COMT protein with methi-
onine at position 158 is reported to be less stable and with reduced
activity[32]. However, this instability can be overcome by the
binding of the methyl cosubstrate for COMT, s-adenosylmethi-
onine (SAM)[52]. MTHFR modulates the availability of methyl
substrates for COMT, including SAM, and the minor ‘‘T’’ allele
of the rs1801133 SNP of MTHFR has been associated with
reduced MTHFR activity and reduced production of SAM[44].
The ATCA haplotype of COMT is the only observed haplotype to
have the ‘‘A’’ allele at the rs4680 loci and we postulated that an
interaction between the ATCA haplotype of COMT and the minor
‘‘T’’ allele of the MTHFR rs1801133 SNP would result in a further
decrease of COMT activity because there would not be adequate
levels of SAM to stabilize the COMT protein. We therefore tested
for epistasis between the ATCA COMT haplotype and SNP
rs1801133 of MTHFR. Results of a multiple logistic regression
model that included maternal and fetal terms for the interaction
between the ATCA COMT haplotype and MTHFR are shown in
Table 6. A significant interaction (P=0.022) between the fetal
ATCA COMT haplotype and the fetal MTHFR was observed,
which resulted in an increased risk for preeclampsia (OR =1.370;
95% CI: 1.048, 1.792). The critical value for the test statistic
associated with the interaction term was also estimated using
permutation techniques and resulted in an empirical p-value of
0.023. No association was found between SNP rs1801133 in
MTHFR and preeclampsia in either maternal or fetal samples
(P=0.470 and P=0.225 respectively).
Our results revealed both a maternal protective effect and a fetal
risk effect. Since our data included maternal-fetal dyads, we looked
at the combination of maternal and fetal effects in a single
pregnancy, focusing on the fetal high risk genotypes. Within cases
we looked at the proportion of pregnancies that had two fetal high
risk COMT ATCA x MTHFR ‘‘T’’ combinations with no maternal
protective COMT ACCG allele and those that contained the two
fetal high risk combinations with a balancing maternal COMT
ACCG allele. We observed a higher than expected number of
patients with preeclampsia with both the fetal risk alleles alone
(Chi-square =3.789; P=0.052) and the fetal risk alleles in
combination with a maternal balancing protective allele (Chi-
square =22.549; P,0.001). This non-random distribution across
dyads was not observed in controls (P=0.341 and P=0.219,
respectively).
Discussion
Preeclampsia is a common disorder of pregnancy with poten-
tially devastating complications[1,53]. Placental hypoxia and
endothelial cell dysfunction are central features of this disor-
der[12]. One proposed mechanism for preeclampsia is placental
hypoxia-driven imbalance of angiogenic and anti-angiogenic
factors[12,18,19,21–24], resulting in endothelial dysfunc-
tion[16,18–20,54]. 2-Hydroxyestrogens are metabolized by
COMT to produce 2-ME, a compound with diverse biological
activities including inhibition of HIF-1a, a transcription factor that
mediates cellular response to hypoxia[26–28]. Epidemiologic data
has consistently demonstrated a strong genetic susceptibility to
preeclampsia and COMT has been identified as a candidate gene
for preeclampsia studies[2,3,27,55]. In the present study, we found
that the maternal ACCG haplotype of COMT, which is associated
with low enzyme activity, was associated with a significantly
Table 5. Maternal COMT analysis for body mass index.
COMT Estimate (S.E.) P-value
SNP rs6269 0.120 (0.231) 0.605
rs4633 20.182 (0.222) 0.413
rs4818 0.092 (0.234) 0.693
rs4680 20.192 (0.223) 0.390
Haplotype ATCA 20.191* 0.392
GCGG 0.114* 0.628
ACCG 0.093* 0.675
Estimate is reported with (Standard Error) for SNPs.
*Standard errors are not calculated for haplotypes by PLINK. COMT haplotype
SNP order: rs6269, rs4633, rs4818, rs4680. S.E., standard error; SNP, single
nucleotide polymorphism.
doi:10.1371/journal.pone.0016681.t005
Table 6. Logistic regression model of COMT-MTHFR interaction risks for preeclampsia.
Term Estimate (S.E.) P-value Odds Ratio (95% C.I.)
Maternal ACCG 20.220 (0.126) 0.080 0.803 (0.627, 1.027)
Fetal ACCG 20.126 (0.134) 0.345 0.882 (0.678, 1.146)
Maternal ATCA 0.017 (0.173) 0.921 1.017 (0.725, 1.428)
Fetal ATCA 20.323 (0.174) 0.064 0.724 (0.515, 1.018)
Maternal MTHFR 20.038 (0.143) 0.792 0.963 (0.727, 1.274)
Fetal MTHFR 20.084 (0.145) 0.563 0.919 (0.692, 1.222)
Maternal ATCA: Maternal MTHFR 20.028 (0.138) 0.840 0.972 (0.742, 1.274)
Fetal ATCA: Fetal MTHFR 0.315 (0.137) 0.022 1.370 (1.048, 1.792)
Maternal BMI 0.102 (0.015) ,0.001 1.107 (1.075, 1.140)
Previous live births 20.252 (0.060) ,0.001 0.777 (0.691, 0.874)
Intercept 22.082 (0.437) ,0.001 -
COMT haplotype SNP order: rs6269, rs4633, rs4818, rs4680. MTHFR SNP rs1801133. S.E., standard error; C.I., confidence interval; BMI, body mass index. An interaction
between the fetal ATCA COMT haplotype and the minor ‘‘T’’ allele of MTHFR significantly increased the risk for preeclampsia; after correcting for risk factors identified to
modulate risk in this population.
doi:10.1371/journal.pone.0016681.t006
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increased in a linear fashion from low to high activity alleles. We
also found that epistasis between fetal COMT and MTHFR, which
is associated with decreased enzyme activity as well, was associated
with significantly increased risk for preeclampsia in this popula-
tion.
We have previously reported that a Comt
2/2 mouse model
exhibits a preeclampsia phenotype that is reversed by administra-
tion of 2-ME[27]. This model lead us to postulate that decreased
production of 2-ME in humans, as a result of allelic variation in
COMT, contributed to the development of preeclampsia[27]. The
results of our current study showed that a maternal haplotype of
COMT, which likely results in decreased levels of maternal 2-ME
production, was in fact protective and decreased the risk for
preeclampsia. In contrast, an interaction between a fetal haplotype
of COMT and fetal MTHFR, which likely results in decreased level
of fetal 2-ME production; increased the risk for preeclampsia as
was initially predicted. A significant limitation to the Comt
2/2
mouse model is that COMT was absent in both the maternal and
fetal compartments. By being deficient in both compartments, it is
unclear whether the preeclampsia-like phenotype is a result of
deficiencies in both compartments, or rather a deficiency in only
one of the compartments. Although our results appear contradic-
tory and do not support our initial hypothesis, we would like to
propose that they are not inconsistent with the mouse model. We
speculate that decreased maternal COMT activity would be
beneficial by increasing the production of 2-ME by the placenta
and that a placental loss of COMT activity is the key deficiency
that contributes to the development of preeclampsia.
Previous research on genetic variation in the COMT gene has
largely focused on a single SNP rs4680, which causes a valine to
methionine substitution at position 158 (Val
158Met) of the
membrane bound version of the protein and position 108 of the
soluble form. This amino acid substitution has been associated
with a 4-fold decrease in activity in homozygote individuals[32].
Three additional SNPs, rs6269, rs4633, and rs4818, have recently
been reported by Nackley et al. to contribute to haplotype
structures with rs4680[33]. Although only rs4680 encodes an
amino acid change, the additional polymorphisms are predicted to
cause changes in mRNA secondary structure and thus, alter
translation of the gene. Three main haplotypes were identified
GCGG, ATCA, and ACCG and functional analysis in a
mammalian expression system revealed changes in enzyme activity
ranging from a decrease of 2.5–3 fold with the intermediate
haplotype, ATCA, to a decrease of 18–25 fold with the low activity
haplotype, ACCG[33]. Decreased activity of the low ACCG
haplotype was attributed to low translation of the protein, while
the decreased activity of the ATCA haplotype was attributed to
impaired stability of the protein as a result an amino acid
substitution at SNP rs4680[33]. Our study supports this conclusion
in that we found the four SNPs to be in very high linkage
disequilibrium and we identified the same three haplotypes in our
Chilean population. Our single SNP analysis showed no significant
results, but haplotype analysis revealed a significant association
between COMT and preeclampsia.
These results are in agreement with several recent studies that
identified COMT haplotype associations with attention deficit
hyperactivity disorder, pain sensitivity, and Parkinson’s dis-
ease[56–58]. Even more compelling, however, is our finding that
preeclampsia risk changed in a linear fashion when we ordered
haplotypes by reported enzymatic function. The ATCA haplotype
was between the ACCG and GCGG haplotypes, with the ACCG
haplotype being associated with the lowest risk for preeclampsia,
and the GCGG haplotype with the highest risk. This progressive
risk supports the assertion by Nackley et al. that ATCA represents
the intermediate activity haplotype, while ACCG and GCGG are
the extremes[33]. The results reported herein have significant
implications not only for research in preeclampsia, but also for
future studies investigating genetic variation in the COMT gene.
Our results suggest that investigating only the COMT rs4680
Val
158Met polymorphism provides incomplete information be-
cause it fails to recognize haplotype structures, which account for
larger variations in enzyme activity. COMT haplotypes therefore
can provide clarification of the role of COMT alleles in disease.
The identification of haplotypes which modulate enzyme activity
to a greater degree than a single polymorphism might explain the
sometimes contradictory results of previous genetic association
studies with other common disease[59,60].
When considering the COMT gene independently, our results
show that the maternal low activity haplotype of COMT, ACCG,
was associated with a significantly lower risk for preeclampsia. The
lower activity of the ACCG COMT haplotype has been reported to
be the result of changes in mRNA secondary structure that lead to
decreased translation of COMT protein[33]. Thus, the protective
maternal effect of COMT on the risk for preeclampsia is likely the
result of a translational mechanism. This significant association
between COMT and preeclampsia highlights the importance of
this gene in preeclampsia, but does not support the causative
mechanism suggested by the Comt knock out mouse. The finding of
a protective effect of a low COMT activity haplotype may suggest
that reduced catecholamine metabolism or 2-ME production in
the maternal compartment spares the placenta from hypoxia.
Decreased metabolism of catecholestrogens in the maternal
compartment would increase the amount circulating through the
placenta and increase the potential production of 2-ME in this
compartment.
Obesity is a major risk factor for preeclampsia and increased
BMI was highly correlated with increased risk for preeclampsia in
our study[48]. COMT metabolizes catecholamines including
dopamine, epinephrine, norepinephrine, and chatecholestrogens.
Catecholamines modulate lipid mobilization by means of adipose
tissue lipolysis[49]. Specifically, estrogen and androgen concen-
trations are involved in body fat regulation and estradiol appears
to stimulate preadipocyte proliferation and differentiation. Addi-
tionally, 2-ME has been shown to inhibit preadipocyte prolifer-
ation and differentiation in vitro[49]. In 2004, Tworoger et al. found
that the rs4680 SNP in COMT modestly affected exercise-induced
fat loss and in 2008, Annerbrink et al. found that the rs4680 SNP
was associated with increased waist-to-hip ratio and abdominal
sagittal diameter[50,51]. In our study, there was no association
between maternal COMT haplotypes or individual SNPs and BMI
(Table 5). While we can conclude that BMI was not driving the
relationship between COMT and the risk for preeclampsia in the
present study, it is not valid to extend these results past the current
sample since individuals with preeclampsia are oversampled in a
case-control study.
Our COMT x MTHFR interaction findings support a similar
finding by Roffman et al. that the low COMT activity allele was
associated with disrupted prefrontal cortex function only in the
presence of a low MTHFR activity allele [47]. In our study, the
ATCA haplotype of COMT increased the risk for preeclampsia
when the fetus also carried a low activity allele of the MTHFR
gene, characterized by the minor ‘‘T’’ allele at SNP rs1801133.
Unlike the translational mechanism proposed to govern the
maternal COMT effect, the mechanism for the COMT x MTHFR
interaction is most likely to be post translational. The ATCA
haplotype of COMT is the only haplotype that alters the amino
acid sequence and it results in a thermodynamically unstable
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binding of its cosubstrate, S-adenosylmethionine (SAM)[52].
MTHFR modulates the availability of SAM and the minor ‘‘T’’
allele at SNP rs1801133 results in lower production of SAM[44].
Therefore, when the fetus carries the ‘‘T’’ allele of MTHFR and
the ATCA haplotype of COMT, the instability of COMT is not
rectified and lower COMT activity is realized.
The identification of a fetal genetic risk factor for preeclampsia
is an important step in understanding the cause(s) of preeclampsia.
The placenta is fetal tissue and our results strengthen the argument
that primary defects in the placenta play a central role in the
development of preeclampsia. Additionally, our findings are
consistent with the observations of reduced placental COMT
activity and suggest that loss of activity in the fetal compartment of
the Comt
2/2 mice appears to be responsible for the development
of disease in this model [27].
Our findings have demonstrated both protective and risk alleles
for COMT in association with the risk for preeclampsia. By
investigating maternal-fetal dyads, we were able to explore the
implications of both, seemingly contradictory, associations in a
single pregnancy. We found a disproportionately high number of
caseswithtwofetalATCACOMTxMTHFR‘‘T’’riskcombinations
and with the two fetal risk combinations and one maternal ACCG
protective COMT allele. What is most striking about our results
however is the much larger chi-square value for the preeclamptic
pregnanciesthathave two fetalriskcombinationsand onebalancing
maternal protective allele versus only having two fetal risk
combinations and no balancing maternal allele (chi-square 22.549
vs. 3.789). The more significant nonrandom distribution of women
with preeclampsia with a maternal protective ACCG COMT allele
suggests that when the fetus is at high risk, it is preferred to have a
maternalprotective ACCGCOMTalleletopotentiallyoffset the risk
to some degree. Consequently, these pregnancies may be more
viable than pregnancies where the fetus is at high risk, but has no
maternal protection from disease. This hypothesis might help
explain the findings in the Comt
2/2 mouse model and the
observation that women with preeclampsia have lower levels of
circulating 2-ME [27]. The balancing combination of maternal and
fetal COMT alleles results in low COMT activity in both the
maternal and fetal compartments and this mimics the low COMT
profile of the knockout mouse. Although our results appear
consistent with the mouse model, further studies are needed to
understand how COMT behaves differently in the maternal and
fetal compartments to modulate the risk for preeclampsia.
Ethnic differences in preeclampsia have been identified.
Increased rates of preeclampsia have been found in African
American, Hispanic, and Asian women compared to white
women, with African Americans having the highest rates[61].
Additionally, maternal-paternal ethnic discordance has been
associated with an increased incidence[61]. These findings
indicate that differences in genetic causes of preeclampsia may
exist between ethnic groups. Global variation in allele frequencies
for both COMT and MTHFR have also been demonstrated
[44,62–67]. Moreover, allele frequencies for both genes are known
to not only differ among major ethnic categories such as
European, Asian, and African American, but substantial variation
has also been demonstrated in subpopulations of each[44,62–67].
Ethnic variation in each gene raises the possibility that different
alleles of COMT and MTHFR could contribute to preeclampsia
risk in different racial groups. The Chilean population in this study
has a genetic background most similar to Western Europeans, and
in particular, those of Spanish decent (2002 census). Future studies
among different ethnic populations are needed to determine if our
results can be extended to other ethnic groups.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the Virginia Commonwealth
University School of Medicine (IRB # HM12520). All patients
provided written informed consent for the collection of samples
and subsequent analysis.
Study design and population
A case-control study was initiated by searching our clinical
database and bank of biological samples and included Hispanic
women and their neonates in the following groups: 1) Cases –
women with preeclampsia and their neonates (n=528 dyads); and
2) Controls – women who delivered at term with a normal
pregnancy outcome and their neonates (n=575 dyads). Partici-
pants received obstetrical care at the So ´tero del Rı ´o Hospital in
Santiago, Chile (an affiliated of the Pontificia Catholic University
of Santiago, Chile). Exclusion criteria included: (1) known major
fetal anomaly or demise; (2) multi-fetal pregnancy; (3) serious
maternal medical illness (renal insufficiency, congestive heart
disease, etc.); (4) refusal to provide written informed consent; and
(5) a clinical emergency, which prevented counseling of the patient
about participating in the study, such as fetal distress or maternal
hemorrhage. All women provided written informed consent before
collection of the samples. The use of clinical data and collection
and utilization of maternal and neonatal blood for research
purposes was approved by the Institutional Review Boards of the
So ´tero del Rı ´o Hospital and the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, NIH, DHHS.
Ethnically, the Chilean population is estimated at nearly 95%
white and mestizo (mixed white and Amerindian); 3% Amerin-
dian; and 2% other. Mixtures between the conquering Spaniards,
largely Andalusians and Basques, and the Mapuches (Araucanians)
produced the principle Chilean racial type (2002 census). There is
no reported evidence to support differences in disease prevalence
amongst Chileans and there is no evidence to support the presence
of group structure within this population. Therefore, population
stratification was determined to not be a source of potential bias in
this study population.
Clinical definitions
Preeclampsia was defined based on the presence of gestational
hypertension (systolic blood pressure $140 mmHg and/or
diastolic blood pressure $90 mmHg) and proteinuria ($300 mg
in a 24-hour urine collection, two or more dipstick measurement
of 1+, or one or more dipstick measurement $2+) according to
ACOG (1) and the National High Blood Pressure Education
Program[1,68]. Patients were considered to have a normal
pregnancy outcome if they did not have any medical, obstetrical,
or surgical complication, and delivered a term neonate ($37
weeks) of appropriate birth weight for gestational age[69] without
complications.
Sample collection
Maternal blood samples were obtained from the mother at the
time of enrollment in the protocol, and from the umbilical cord
immediately after delivery before the detachment of the placenta.
Samples were collected with a vacutainer into tubes containing
EDTA. The plasma tubes were balanced and centrifuged at
1300 g for 10 minutes at 4uC to separate cellular components from
clear plasma, and the samples were stored at 270uC until assay.
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DNA was extracted from maternal and cord blood with a
Qiagen Autopure using standard procedures (Qiagen).
Genotyping
Single-nucleotide polymorphism analysis was performed using
real-time allelic discrimination TaqMan assays (Applied Biosys-
tems) with modifications. All PCR reactions contained 25–75 ng
of DNA, 6.25 ul TaqMan Universal Master Mix (Applied
Biosystems) (2x), 0.3 ul TaqMan Genotyping Assay (Applied
Biosystems) (20x), and water for a final volume of 12.5 ul. Real-
time PCR was performed on an ABI 7500 Fast Real-Time PCR
Machine (Applied Biosystems) under the following conditions:
50uC for 2 min, 95uC for 10 min, and 40 cycles of amplification
(92uC for 15 sec and 60uC for 1 min). For each cycle, the software
determined the fluorescent signal from the VIC- or FAM- labeled
probe (Applied Biosystems). Allelic discrimination for COMT was
performed using TaqMan Genotyping assays C___2538746_1 for
SNP rs6269, C___2538747_20 for SNP rs4633, C___2538750_10
for SNP rs4818, C__25746809_50 for SNP rs4680 (Applied
Biosystems). Allelic discrimination for MTHFR was performed
using TaqMan Genotyping assay C__1202883_20 for SNP
rs1801133.
Statistical Analysis
Fisher’s exact tests implemented in the PLINK software[70]
were used to test individual SNPs for allelic associations with case-
control status and to confirm Hardy-Weinberg equilibrium in the
control group only. Inter-SNP linkage disequilibrium calculations
for COMT were performed in Haploview (version 4.0)[71].
Haplotype frequencies were also generated in PLINK based on
the four COMT SNPs and both global and haplotype-specific tests
were performed to test for frequency differences between disease
status for maternal and fetal samples separately. Haplotypes with
an independent effect were further investigated by multiple logistic
regression in R to condition by covariates known to influence rates
of preeclamsia and to adjust for the correlation between maternal-
fetal genotypes. These tests involved assigning haplotypes to
subjects based on the most likely phase reconstructed haplotypes
generated by the expectation-maximization algorithm implement-
ed in PLINK. An additive term for the haplotype of interest was
coded as 0, 1, or 2 based on copy number present. Based on the
previously mentioned haplotype-specific functional information
from Nackley et al.[33], we also coded COMT haplotypes to reflect
enzymatic activity. COMT haplotypes were sequentially ordered 1
through 5 where 1 was ACCG/ACCG, 2 was ACCG/ATCA, 3
was ATCA/ATCA, 4 was ATCA/GCGG, and 5 was GCGG/
GCGG. Interactive effects between the maternal ATCA COMT
haplotype and maternal MTHFR and the fetal ATCA COMT
haplotype and fetal MTHFR were tested using multiple logistic
regression in R. The MTHFR was included as an additive term
coded as 0, 1, or 2 based on copy number of the minor ‘‘T’’ allele.
Permutation analysis in R with 10,000 iterations was used to
compare models with and without significant interaction terms.
Logistic regression in R was used to test for differences in clinical
characteristics between disease classes for non-genetic variables.
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